Sort   by:  
 Page size 
UnknownHealth system costs for cancer medications and radiation treatment in Ontario for the 4 most common cancers: a retrospective cohort study.
Not available
S-EPMC7082106 | biostudies-literature
UnknownOverall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL).
Not available
S-EPMC2924992 | biostudies-literature
UnknownCanadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer.
Not available
S-EPMC6380642 | biostudies-literature
UnknownTrends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada.
Not available
S-EPMC11764221 | biostudies-literature
UnknownAnalysis of outcomes in resected early-stage NSCLC with rare targetable driver mutations.
Not available
S-EPMC11672496 | biostudies-literature
UnknownBleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study.
Not available
S-EPMC3049570 | biostudies-literature
UnknownSecond and later-line erlotinib use in non-small cell lung cancer: real world outcomes and practice patterns overtime in Canada.
Not available
S-EPMC8482335 | biostudies-literature
UnknownMetabolites as Prognostic Markers for Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Platinum-Doublet Chemotherapy.
Not available
S-EPMC7409233 | biostudies-literature
UnknownEstimation of drug cost avoidance and pathology cost avoidance through participation in NCIC Clinical Trials Group phase III clinical trials in Canada.
Not available
S-EPMC4780589 | biostudies-literature
UnknownCan Oncologists Predict the Efficacy of Treatments in Randomized Trials?
Not available
S-EPMC7794184 | biostudies-literature
Sort   by:  
 Page size